Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in IntangiblesChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lexaria Bioscience (LEXX) Change in Cash (2016 - 2026)

Lexaria Bioscience's Change in Cash history spans 12 years, with the latest figure at $846908.0 for Q1 2026.

  • Quarterly results put Change in Cash at $846908.0 for Q1 2026, up 152.63% from a year ago — trailing twelve months through Feb 2026 was -$1.3 million (down 176.03% YoY), and the annual figure for FY2025 was -$4.7 million, down 191.26%.
  • Change in Cash for Q1 2026 was $846908.0 at Lexaria Bioscience, down from $2.5 million in the prior quarter.
  • In the past five years, Change in Cash ranged from a high of $3.8 million in Q2 2024 to a low of -$2.8 million in Q3 2025.
  • The 5-year median for Change in Cash is -$1.3 million (2023), against an average of -$267890.0.
  • The sharpest move saw Change in Cash skyrocketed 3569.34% in 2024, then plummeted 158.49% in 2025.
  • Year by year, Change in Cash stood at -$1.3 million in 2022, then surged by 147.03% to $602063.0 in 2023, then surged by 162.16% to $1.6 million in 2024, then surged by 57.07% to $2.5 million in 2025, then plummeted by 65.84% to $846908.0 in 2026.
  • According to Business Quant data, Change in Cash over the past three periods came in at $846908.0, $2.5 million, and -$2.8 million for Q1 2026, Q4 2025, and Q3 2025 respectively.